// App-Quantinova.ai

: Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study

Researchers

Presenter

  • Marie Maerevoet

Principal Investigators

  • Miguel A. Canales

  • Ren-Olivier Casasnovas

  • Eric Van Den Neste

  • Andre Goy

  • Brian T. Hill

  • Catherine Thieblemont

  • Maria De Fatima De La Cruz

  • Federica Cavallo

  • George Follows

  • Sylvain Choquet

  • Ronit Gurion

  • Reda Bouabdallah

  • Ulrich Jaeger

  • Agnes Nagy

  • John Kuruvilla

  • Krzysztof Warzocha

  • Nagesh Kalakonda

  • Paolo Caimi

  • Sameer Bakhshi

  • Matthew Ku

  • Nada Hamad

  • Hendrik Veelken

  • Ewa Matczak

  • Xiwen Ma

  • Jean-Richard Saint-Martin

  • Jatin J. Shah

  • Michael G. Kauffman

  • Sharon Shacham

  • Jose M Zijlstra

Medical Centers

  • Institute Jules Bordet, Brussels, Belgium

  • Department of Urology, Leiden Unviersity Medical Center, Leiden, Netherlands

  • Hospital Universitario La Paz, Madrid, Spain

  • CHU Dijon, Dijon, FRA

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • John Theurer Cancer Ctr At Hackensack Univ Med Ctr, Hackensack, NJ

  • Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

  • Hospital Saint Antoine, Paris, France

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • University of Torino, Department of Molecular Biotechnology and Health Sciences, Torino, Italy

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Gruope Hospitalier Pitie-Salpetriere, Paris, France

  • Rabin Medical Center, Petach Tikvah, Israel

  • Institut Paoli Calmettes, Department of Medical Oncology, Marseille, France

  • Dept. of Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

  • University of Pecs, Pecs, Hungary

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Department of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa,

  • Department of Gastroenterology, University of Liverpool, Liverpool, United Kingdom

  • Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH

  • Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

  • Department of Haematology, St Vincent's Hospital, Darlinghurst, Australia

  • St Vincents Hospital, Sydney, Australia

  • Karyopharm Therapeutics, Newton, MA

  • Department of Hematology, Amsterdam UMC, Vrije Universiteit Cancer Center, Amsterdam, Netherlands

Locations

  • Belgium

  • Netherlands

  • Spain

  • United States

  • France

  • Italy

  • United Kingdom

  • Austria

  • Hungary

  • Canada

  • Poland

  • India

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Selinexor

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT01607892

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved